Tarenflurbil, Flurizan or R-flurbiprofen, is a single enantiomer of the racemate NSAID flurbiprofen.  For several years, research and trials for the drug were conducted by Myriad Genetics, to investigate its potential as a treatment for Alzheimer's disease; that investigation concluded in June 2008 when the company announced it would discontinue development of the compound.